Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, is rescheduling its intra-quarter webcast and investor update call to June 17, 2025, from June 3, 2025, to allow for the implementation of a reverse stock split that will become effective on June 2, 2025.
Prepared remarks by members of the Applied DNA management team will be followed by a live question-and-answer session with the Company's sell-side analysts and institutional investors.
Webcast and Conference Call Date & Time: Tuesday, June 17 @ 4:30 p.m. Eastern Time
Dial In:
Domestic callers (toll-free): 844-887-9402International callers: 412-317-6798Canadian callers (toll-free): 866-605-3852Live webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Ky09znsL
A replay of the conference call will be available for 7 days following the conclusion of the call:
Replay for domestic callers (toll-free): 877-344-7529, replay access code 3446494Replay for international callers: 412-317-0088, replay access code 3446494Replay for Canadian callers (toll-free): 855-669-9658, replay access code 3446494
An accompanying slide presentation will be embedded in the webcast (live and replay) that will also be accessible as a stand-alone document via the 'Company Presentations' page of the Applied DNA investor relations website. The webcast replay of the call will be available approximately one hour after the end of the call on the 'Company Events' page.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
For additional information:
Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: https://investors.adnas.com/
SOURCE: Applied DNA Sciences, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC Sports
13 minutes ago
- NBC Sports
2025 NBA Free Agency Live Tracker: Updates, news, rumors, top players, signings, trades
Oklahoma City has set the bar and the chase to beat them — or at least the race toward respectability — gets serious on Monday with the official start of NBA free agency and the peak of the NBA trade season. Not that every team has waited — Kevin Durant is now a Houston Rocket and they are all-in on winning next season. Desmond Bane is in Orlando already, where he is an underrated fit with an up-and-coming Magic team. As of Monday at 6 p.m. Eastern, teams are officially allowed to start talking to free agents (although, in the tampering world of the NBA, if a team is not already at least two-thirds done with free agency by the time it starts, they are behind). In this tracker, we will give you all the latest signings, trades, rumors, and reports all in one place (all in order of when they happened, with the most recent news on top). This is a brief synopsis with initial thoughts on any deals; follow the links to view a more detailed analysis. Clippers, Nicolas Batum agree to new deal For a player scoring 4 points a game and averaging less than 18 minutes a night, it's difficult to overstate how much Nicolas Batum means to the Clippers. He steadies their bench units, provides needed leadership, and is a hand-in-glove fit for how the Clippers want to play. Which is why the Clippers are giving him as large a deal as they can with his non-Bird rights — $11.5 million over two years — to return, a story broken by ESPN's Shams Charania. Even with this deal and the team re-signing James Harden, the Clippers are $8.5 million below the luxury tax line, affording them the flexibility to bring in a player at the full mid-level exception ($14.1 million) or make a bold trade. Keep an eye on this team, they are in the middle of a lot of rumors around the league. Jazz, Jordan Clarkson agree to buyout Add Jordan Clarkson to the list of free agents. Clarkson averaged 16.2 points a game last season while shooting 36.2% from 3, and he wanted to be moved to a contender, but there was no trade market because of his $14.3 million contract. So, the Jazz and Clarkson have agreed to a contract buyout, reports ESPN's Shams Charania. With this buyout — where Clarkson certainly is giving the Jazz a discount, how much we don't yet know — he becomes a free agent. There will be interest from playoff teams who want to add some bench scoring, just didn't want to do it at the price he was getting paid. Expect now a taxpayer mid-level sized contract ($5.7 million) or less. Nets bring back DayRon Sharpe, Ziaire Williams By keeping all five of their first-round draft picks this year, the Brooklyn Nets are leaning hard into youth and a rebuild. With that, the Nets made a couple of moves before free agency opened Monday. First, they are bringing back big man DayRon Sharpe. This is a player the Nets didn't extend a qualifying offer to, making him an unrestricted free agent. However, the sides agreed to a two-year, $12 million contract, a story broken by ESPN's Shams Charania. Sharpe averaged 7.9 points and, 6.6 rebounds a game for the Nets last season. Second, the Nets are re-signing wing Ziaire Williams on a two-year, $12 million contract, Charania reports. Last season, Williams started more than half the Nets' games and averaged 10 points and 4.6 rebounds a night.
Yahoo
13 minutes ago
- Yahoo
Why Magnite (MGNI) Stock Is Up Today
Shares of digital advertising platform Magnite (NASDAQ:MGNI) jumped 13.8% in the afternoon session after it hit a new 52-week high, largely driven by a substantial price target increase from Rosenblatt. The investment firm raised its target to $39 from $18, citing potential benefits for Magnite from the ongoing AdTech antitrust ruling against Google. Is now the time to buy Magnite? Access our full analysis report here, it's free. Magnite's shares are extremely volatile and have had 33 moves greater than 5% over the last year. But moves this big are rare even for Magnite and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 14 days ago when the stock gained 6.8% on the news that the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran. The Wall Street Journal said senior Iranian officials had signaled a willingness to restart stalled nuclear talks, on the condition that Washington refrain from joining Israel's ongoing strikes. This development triggered a significant decline in oil prices, easing inflation concerns. Magnite is up 48.7% since the beginning of the year, and at $23.93 per share, has set a new 52-week high. Investors who bought $1,000 worth of Magnite's shares 5 years ago would now be looking at an investment worth $3,589. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
14 minutes ago
- Yahoo
Signal: Aerospace Stock Ready to Take Off
FTAI Aviation Ltd (NASDAQ:FTAI) stock is down 2.7% to trade at $115.34, heading for its lowest close since May 23. The aerospace concern is down 19.9% in 2025, but if past is precedent, could be ready to rally. FTAI is within one standard deviation of its 50-day moving average. For the purpose of this study, Schaeffer's Senior Quantitative Analyst Rocky White defines that as the equity trading above the moving average 80% of the time over the last two months, and closing north of the trendline in eight of the last 10 sessions. Per White's data, 11 similar signals have occurred during the past three years. FTAI was higher one month later 82% of the time, averaging a one-month gain of 10.1%. From its current perch, a move of similar magnitude would put the stock back in its consolidation area, and eat into its nine-month deficit of 13.3%. Also worth noting on the chart below is the double bottom from earlier in the summer. A short squeeze could nudge the shares along as well. Short interest fell 15.4% in the two most recent reporting periods, yet the 6.27 million shares sold short still account for 6.2% of FTAI's total available float. At the equity's average pace of trading, it would take shorts almost four trading days to buy back their bearish bets. Options are an attractive choice, per the equity's Schaeffer's Volatility Index (SVI) of 56% that sits in the 20th percentile of its annual range. This suggests options traders have lower-than-usual volatility expectations. FTAI has consistently exceeded their volatility estimates though, as reflected in its Schaeffer's Volatility Scorecard (SVS) score of 90 out of 100. In other words, the security has historically delivered larger-than-expected price swings. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
